CALDEIRÃO DE BOLSA

Minsk Escreveu:

BearManBull Escreveu::arrow:

Boas BearMan,

Não entendi o objectivo do gráfico. Queres mostrar que a tendência mp é ainda bear ou que acabou de romper a linha de tendência bear e está bull curto prazo?

Eu vejo a GRF de outro modo. Tem tido historicamente um suporte nos 19-20 que tem sempre respondido muito bem com ressaltos fortes. A empresa sofreu com a pandemia porque depende de doações de plasma (nos US são pagos) e o confinamento mundial basicamente fechou a torneira. Com o reabrir da economia e imunidade de grupo as doações vão retomar, e já estão de facto a retomar.
Tem investido muito em novos centros de recolha de plasma nos US para aumentar a matéria prima. Tem cash flow forte embora dívida também bastante elevada.
Entrei a 21,5 a aproveitar a volatilidade e creio que a empresa voltará pelo menos aos 25 no médio prazo.

BearManBull Escreveu::arrow:

cali010201 Escreveu:Já tive em tempos ações da GRIFOLS e quando as vendi, tive dupla tributação - paguei impostos sobre mais valias na Espanha e paguei novamente em Portugal, ou seja, mais de metade dos lucros foi gasta em impostos...

Grifols Jumps as Exane Expects Increase in Plasma Pricing

Grifols SA (GRF), Europe's largest maker of blood-plasma products, jumped the most in six months after Exane BNP Paribas said the global market for protein therapies derived from the material will expand in the next two years.

Grifols rose as much as 4.9 percent to 28.71 euros, the biggest intraday gain since Oct. 5, and was trading up 4.5 percent at 1:43 p.m. in Madrid in the biggest gain on the 35- stock Stoxx 600 Health Care Index. (SXDP) Volume was 68 percent of the three-month daily average.

Prices charged by the top three plasma-therapy makers have increased as much as 4 percent for the second year in a row in the U.S. as capacity use for the products is expected to reach a 10-year high of as much as 90 percent through 2015, Julien Dormois, a Paris-based analyst at Exane BNP Paribas, wrote in a report. Dormois, who has an outperform recommendation on Barcelona-based Grifols, raised his stock-price estimate by 21 percent to 35 euros.

CSL Plasma Inc., Baxter International Inc. (BAX) and Grifols control almost 70 percent of the plasma market, and “we see strong upside” from accelerating industrywide growth, Dormois wrote yesterday. “Pricing power is back.”

Grifols purchased North-Carolina based plasma collector Talecris Biotherapeutics Holdings Corp. in June 2011 to expand in the $7 billion U.S. market for blood-based infusions, used to treat rare and life-threatening conditions.

The U.S. accounted for 64 percent of Grifols’s revenue last year, according to data compiled by Bloomberg. Grifols owns 150 plasma donation centers in the country, where the company collected 5.8 million liters of plasma in 2012, the Exane analyst said. The Talecris unit offers average prices of as much as $200 a month to blood donors, according to the division’s website.

Plasma is the clear, liquid portion of blood which contains a large number of proteins, particularly those responsible for blood clotting and protecting the body from infections.

correia1978 Escreveu:Novos máximos absolutos na Grifols: 27,22€.